OpenURL Connection Search

Select item for more details and to access through your institution.

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
Published in:
Breast Cancer Research & Treatment, 2020, v. 179, n. 3, p. 677, doi. 10.1007/s10549-019-05495-3
By:
- Claessens, Anouk K. M.;
- Timman, Reinier;
- Busschbach, Jan J.;
- Bouma, Jeanette M.;
- Rademaker-Lakhai, Jeany M.;
- Erdkamp, Frans L. G.;
- Tjan-Heijnen, Vivianne C. G.;
- Bos, Monique E. M. M.
Publication type:
Article
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Published in:
Breast Cancer Research & Treatment, 2018, v. 172, n. 2, p. 413, doi. 10.1007/s10549-018-4906-8
By:
- Claessens, Anouk K. M.;
- Bos, Monique E. M. M.;
- Lopez-Yurda, Marta;
- Bouma, Jeanette M.;
- Rademaker-Lakhai, Jeany M.;
- Honkoop, Aafke H.;
- de Graaf, Hiltje;
- van Druten, Edith;
- van Warmerdam, Laurence J. C.;
- van der Sangen, Maurice J. C.;
- Tjan-Heijnen, Vivianne C. G.;
- Erdkamp, Frans L. G.;
- The Dutch Breast Cancer Research Group (BOOG)
Publication type:
Article
Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.
Published in:
2022
By:
- Claessens, Anouk K. M.;
- Busschbach, Jan J. V.;
- Ramaekers, Bram L. T.;
- Erdkamp, Frans L. G.;
- Bouma, Jeanette M.;
- van Leeuwen-Stok, A. Elise;
- Tjan-Heijnen, Vivianne C. G.;
- Bos, Monique E. M. M.
Publication type:
Letter
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
Published in:
Acta Oncologica, 2020, v. 59, n. 6, p. 713, doi. 10.1080/0284186X.2020.1731923
By:
- Claessens, Anouk K. M.;
- Erdkamp, Frans L. G.;
- Lopez-Yurda, Marta;
- Bouma, Jeanette M.;
- Rademaker-Lakhai, Jeany M.;
- Honkoop, Aafke H.;
- de Graaf, Hiltje;
- Tjan-Heijnen, Vivianne C. G.;
- Bos, Monique E. M. M.
Publication type:
Article

Found: 4

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).

Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.

Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.